Replies to post #327139 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

DON'T UNDERESTIMATE SPA: Cassava will be PRing the hell for next 3 years while enrolling and readout of data.

With precise focused target, they maybe fill trial in 6 months. So a 52 weeks trial will only be about 8 months behind the completion of our trial.

With focused target, their data analysis and FDA filing takes 4 months instead of 1 year like ours did for PDD. So they made up the 8 months. It's a dead heat.

FDA gets their filing and only has to confirm that SAVA hit SPA pre-agreed targets. So FD decision takes 3 months less for SAVA.

Result is SAVA is first to market, reaps all the free publicity of having an alz treatment approved.

FDA is off the Biogen hook, so no rush to review AVXL's application for 273.

273 is approved 6-12 months after SAVA's drug, now has to convince doctors to switch instead of free publicity that first on approved gets